BULLISHWHALES
BullishWhales · Analysts · Analyst Profile
BW Score Rank#269 of 347

Gil Blum

Needham · Equity Research Analyst
EstablishedRating since 2021No new ratings since Jun 2025

Analyst rating accuracy & track record

Gil Blum is an equity research analyst at Needham. Bullish Whales has scored 82 of their stock calls across 12 companies. Their picks beat their sector 24% of the time over the next 12 months, and their price targets were reached 18% of the time within a year.

Win % vs sector
24%
PT Hit % (12mo)
18%
Avg sector-excess
−15.4%
Scored calls
82
Tickers
12
Tier
Established

Track record

Bullish Whales has scored 82 of Gil Blum's stock calls across 12 companies, dating back to 2021. Their rated stocks beat their own sector 24% of the time over the next 12 months. On a typical call, a Blum pick returned −15.4% more than its sector over the following year.

Of the scored calls, 82 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
TSHATaysha Gene Therapies Inc
Buy$8.00Jun 2025+87.6%Miss
TSHATaysha Gene Therapies Inc
Buy$8.00Jun 2025+92.7%Miss
NKTXNkarta Inc
Buy$10.00May 2025+40.8%Miss
ARTVArtiva Biotherapeutics, Inc. Common Stock
Buy$18.00May 2025+370.8%Miss
ABSIAbsci Corp
Buy$9.00May 2025+74.0%Miss
MREOMereo BioPharma Group PLC ADR
Buy$7.00May 2025−104.7%Miss
RNACCartesian Therapeutics Inc.
Buy$40.00May 2025−22.7%Miss
RXRXRecursion Pharmaceuticals Inc
Buy$8.00May 2025−27.5%Miss
TSHATaysha Gene Therapies Inc
Buy$6.00Apr 2025+251.1%Hit
IMCRImmunocore Holdings Ltd
Buy$71.00Apr 2025+7.2%Miss
NKTXNkarta Inc
Buy$11.00Apr 2025+40.3%Miss
MREOMereo BioPharma Group PLC ADR
Buy$7.00Apr 2025−95.2%Miss
RNACCartesian Therapeutics Inc.
Buy$41.00Apr 2025−53.0%Miss
ABSIAbsci Corp
Buy$9.00Apr 2025+7.5%Miss
RXRXRecursion Pharmaceuticals Inc
Buy$11.00Apr 2025−36.9%Miss
ARTVArtiva Biotherapeutics, Inc. Common Stock
Buy$23.00Apr 2025+201.3%Miss
NKTXNkarta Inc
Buy$11.00Mar 2025+2.1%Miss
MREOMereo BioPharma Group PLC ADR
Buy$7.00Mar 2025−88.3%Miss
ARTVArtiva Biotherapeutics, Inc. Common Stock
Buy$23.00Mar 2025+47.2%Miss
ABSIAbsci Corp
Buy$9.00Mar 2025−0.2%Miss
RNACCartesian Therapeutics Inc.
Buy$41.00Mar 2025−58.4%Miss
GERNGeron Corporation
Buy$5.00Mar 2025−10.4%Miss
IMCRImmunocore Holdings Ltd
Buy$71.00Mar 2025+3.6%Miss
GERNGeron Corporation
Buy$5.00Feb 2025−14.0%Miss
TSHATaysha Gene Therapies Inc
Buy$6.00Feb 2025+173.7%Hit
IMCRImmunocore Holdings Ltd
Buy$71.00Feb 2025+0.5%Miss
RXRXRecursion Pharmaceuticals Inc
Buy$11.00Feb 2025−56.5%Hit
RNACCartesian Therapeutics Inc.
Buy$41.00Jan 2025−70.9%Miss
ABSIAbsci Corp
Buy$9.00Jan 2025−36.0%Miss
GERNGeron Corporation
Buy$7.00Jan 2025−69.4%Miss
MREOMereo BioPharma Group PLC ADR
Buy$7.00Jan 2025−92.4%Miss
RNACCartesian Therapeutics Inc.
Buy$41.00Jan 2025−71.4%Miss
TSHATaysha Gene Therapies Inc
Buy$6.00Jan 2025+164.6%Hit
MREOMereo BioPharma Group PLC ADR
Buy$7.00Dec 2024−56.0%Miss
GERNGeron Corporation
Buy$6.00Dec 2024−79.1%Miss
ACLXArcellx Inc
Buy$105.00Dec 2024−26.2%Miss
ACLXArcellx Inc
Buy$105.00Dec 2024−19.8%Miss
RNACCartesian Therapeutics Inc.
Buy$41.00Nov 2024−71.3%Miss
RXRXRecursion Pharmaceuticals Inc
Buy$11.00Nov 2024−40.1%Hit
ARTVArtiva Biotherapeutics, Inc. Common Stock
Buy$23.00Nov 2024−75.3%Miss
MREOMereo BioPharma Group PLC ADR
Buy$7.00Nov 2024−60.5%Miss
NKTXNkarta Inc
Buy$11.00Nov 2024−42.6%Miss
RNACCartesian Therapeutics Inc.
Buy$41.00Nov 2024−63.8%Miss
RXRXRecursion Pharmaceuticals Inc
Buy$11.00Nov 2024−34.0%Hit
IMCRImmunocore Holdings Ltd
Buy$71.00Nov 2024−2.5%Miss
RNACCartesian Therapeutics Inc.
Buy$41.00Oct 2024−51.6%Miss
RXRXRecursion Pharmaceuticals Inc
Buy$11.00Sep 2024−17.2%Hit
ARTVArtiva Biotherapeutics, Inc. Common Stock
Buy$23.00Aug 2024−61.1%Miss
NKTXNkarta Inc
Buy$13.00Aug 2024−45.3%Miss
MREOMereo BioPharma Group PLC ADR
Buy$7.00Aug 2024−45.5%Miss
Go to

Gil Blum: analyst track record FAQ

Is Gil Blum a good stock analyst?

Yes, by track record. Gil Blum ranks number 269 of 347 of the analysts Bullish Whales scores, with a BW Score of 4 out of 100. Past results do not guarantee future ones.

What is Gil Blum's win rate?

Gil Blum's win rate is 24%. Across 82 scored calls, their rated stocks beat their sector 24% of the time over the next 12 months. On a typical call they returned −15.4% more than the sector.

What stocks and sectors does Gil Blum cover?

Gil Blum covers 12 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Gil Blum's price targets accurate?

Gil Blum's price targets are reached within 12 months 18% of the time. The base rate across all analysts Bullish Whales tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Bullish Whales scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Gil Blum's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Bullish Whales score analyst accuracy?

Bullish Whales scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Gil Blum rank among Wall Street analysts?

Gil Blum ranks number 269 of 347 by BW Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.

v1.0.30